{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T04:55:32Z","timestamp":1789620932203,"version":"build-2803163510"},"reference-count":65,"publisher":"Cold Spring Harbor Laboratory","issue":"12","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cold Spring Harb Perspect Med"],"published-print":{"date-parts":[[2018,12]]},"DOI":"10.1101\/cshperspect.a029066","type":"journal-article","created":{"date-parts":[[2018,3,3]],"date-time":"2018-03-03T01:20:17Z","timestamp":1520040017000},"page":"a029066","source":"Crossref","is-referenced-by-count":24,"title":["Natalizumab: Perspectives from the Bench to Bedside"],"prefix":"10.1101","volume":"8","author":[{"given":"Afsaneh","family":"Shirani","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olaf","family":"St\u00fcve","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"246","published-online":{"date-parts":[[2018,3,2]]},"reference":[{"key":"2020072712443348000_8.12.a029066.1","doi-asserted-by":"publisher","DOI":"10.1007\/s40263-015-0238-y"},{"key":"2020072712443348000_8.12.a029066.2","doi-asserted-by":"publisher","DOI":"10.1177\/0890334414566237"},{"key":"2020072712443348000_8.12.a029066.3","doi-asserted-by":"publisher","DOI":"10.1177\/1352458509347154"},{"key":"2020072712443348000_8.12.a029066.4","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1007\/s13365-016-0431-x","article-title":"Erratum to: Reassessing the risk of natalizumab-associated PML","volume":"22","year":"2016","journal-title":"J Neurovirol"},{"key":"2020072712443348000_8.12.a029066.5","doi-asserted-by":"publisher","DOI":"10.1007\/s13365-016-0427-6"},{"key":"2020072712443348000_8.12.a029066.6","doi-asserted-by":"publisher","DOI":"10.1179\/016164106X98198"},{"key":"2020072712443348000_8.12.a029066.7","first-page":"495","article-title":"The pathogenesis of progressive multifocal leukoencephalopathy","volume":"12","year":"2011","journal-title":"Discov Med"},{"key":"2020072712443348000_8.12.a029066.8","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMe058122"},{"key":"2020072712443348000_8.12.a029066.9","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.1111\/j.1365-2036.2010.04262.x","article-title":"Clinically significant liver injury in patients treated with natalizumab","volume":"31","year":"2010","journal-title":"Aliment Pharmacol Ther"},{"key":"2020072712443348000_8.12.a029066.10","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1107829"},{"key":"2020072712443348000_8.12.a029066.11","doi-asserted-by":"publisher","DOI":"10.1126\/science.272.5258.60"},{"key":"2020072712443348000_8.12.a029066.12","doi-asserted-by":"publisher","DOI":"10.1586\/14737175.8.3.433"},{"key":"2020072712443348000_8.12.a029066.13","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp-2013-306936"},{"key":"2020072712443348000_8.12.a029066.14","doi-asserted-by":"publisher","DOI":"10.1212\/01.wnl.0000277457.17420.b5"},{"key":"2020072712443348000_8.12.a029066.15","doi-asserted-by":"crossref","first-page":"1445","DOI":"10.1185\/03007990902876040","article-title":"Cost effectiveness and budget impact of natalizumab in patients with relapsing multiple sclerosis","volume":"25","year":"2009","journal-title":"Curr Med Res Opin"},{"key":"2020072712443348000_8.12.a029066.16","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(10)70028-4"},{"key":"2020072712443348000_8.12.a029066.17","doi-asserted-by":"publisher","DOI":"10.1177\/1352458514531843"},{"key":"2020072712443348000_8.12.a029066.18","doi-asserted-by":"publisher","DOI":"10.1097\/WCO.0000000000000321"},{"key":"2020072712443348000_8.12.a029066.19","doi-asserted-by":"publisher","DOI":"10.1177\/1352458514546790"},{"key":"2020072712443348000_8.12.a029066.20","doi-asserted-by":"publisher","DOI":"10.1016\/0092-8674(90)90661-W"},{"key":"2020072712443348000_8.12.a029066.21","doi-asserted-by":"publisher","DOI":"10.1177\/1756285612470401"},{"key":"2020072712443348000_8.12.a029066.22","doi-asserted-by":"publisher","DOI":"10.1007\/s00415-012-6414-9"},{"key":"2020072712443348000_8.12.a029066.23","doi-asserted-by":"publisher","DOI":"10.1097\/NRL.0b013e318148c08e"},{"key":"2020072712443348000_8.12.a029066.24","doi-asserted-by":"crossref","first-page":"617","DOI":"10.2165\/00019053-200826070-00008","article-title":"Cost-effectiveness analyses of natalizumab (Tysabri) compared with other disease-modifying therapies for people with highly active relapsing-remitting multiple sclerosis in the UK","volume":"26","year":"2008","journal-title":"Pharmacoeconomics"},{"key":"2020072712443348000_8.12.a029066.25","doi-asserted-by":"publisher","DOI":"10.1212\/01.wnl.0000343880.13764.69"},{"key":"2020072712443348000_8.12.a029066.26","doi-asserted-by":"publisher","DOI":"10.1002\/ana.22128"},{"key":"2020072712443348000_8.12.a029066.27","doi-asserted-by":"publisher","DOI":"10.1098\/rspb.1964.0001"},{"key":"2020072712443348000_8.12.a029066.28","first-page":"114","article-title":"Th17 cells: A prognostic marker for MS rebound after natalizumab cessation?","volume":"23","year":"2016","journal-title":"Mult Scler"},{"key":"2020072712443348000_8.12.a029066.29","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1001\/jamaneurol.2014.209","article-title":"Natalizumab use during the third trimester of pregnancy","volume":"71","year":"2014","journal-title":"JAMA Neurol"},{"key":"2020072712443348000_8.12.a029066.30","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000001608"},{"key":"2020072712443348000_8.12.a029066.31","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000002586"},{"key":"2020072712443348000_8.12.a029066.32","doi-asserted-by":"publisher","DOI":"10.1212\/01.wnl.0000341766.59028.9d"},{"key":"2020072712443348000_8.12.a029066.33","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa051782"},{"key":"2020072712443348000_8.12.a029066.34","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa051847"},{"key":"2020072712443348000_8.12.a029066.35","first-page":"72","article-title":"Immunological and pathological characterization of fatal rebound MS activity following natalizumab withdrawal","volume":"23","year":"2016","journal-title":"Mult Scler"},{"key":"2020072712443348000_8.12.a029066.36","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1007\/s10072-010-0427-x","article-title":"Association of melanoma and natalizumab therapy in the Italian MS population: A second case report","volume":"32","year":"2011","journal-title":"Neurol Sci"},{"key":"2020072712443348000_8.12.a029066.37","doi-asserted-by":"publisher","DOI":"10.1007\/s10072-010-0356-8"},{"key":"2020072712443348000_8.12.a029066.38","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa020696"},{"key":"2020072712443348000_8.12.a029066.39","doi-asserted-by":"publisher","DOI":"10.1212\/01.WNL.0000128136.79044.D6"},{"key":"2020072712443348000_8.12.a029066.40","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0b013e31821e7c8a"},{"key":"2020072712443348000_8.12.a029066.41","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000000541"},{"key":"2020072712443348000_8.12.a029066.42","doi-asserted-by":"publisher","DOI":"10.3111\/13696998.2011.602444"},{"key":"2020072712443348000_8.12.a029066.43","first-page":"1092","article-title":"Multiple sclerosis treatment: Risk mitigation","volume":"19","year":"2013","journal-title":"Continuum (Minneap Minn)"},{"key":"2020072712443348000_8.12.a029066.44","doi-asserted-by":"publisher","DOI":"10.1016\/0092-8674(89)90775-7"},{"key":"2020072712443348000_8.12.a029066.45","doi-asserted-by":"publisher","DOI":"10.1007\/s10072-010-0345-y"},{"key":"2020072712443348000_8.12.a029066.46","doi-asserted-by":"publisher","DOI":"10.2147\/PROM.S41768"},{"key":"2020072712443348000_8.12.a029066.47","doi-asserted-by":"publisher","DOI":"10.1002\/ana.24286"},{"key":"2020072712443348000_8.12.a029066.48","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa044397"},{"key":"2020072712443348000_8.12.a029066.49","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa044396"},{"key":"2020072712443348000_8.12.a029066.50","doi-asserted-by":"crossref","first-page":"1247","DOI":"10.1586\/ern.11.109","article-title":"What happens when natalizumab therapy is stopped?","volume":"11","year":"2011","journal-title":"Expert Rev Neurother"},{"key":"2020072712443348000_8.12.a029066.51","doi-asserted-by":"publisher","DOI":"10.1212\/NXI.0000000000000195"},{"key":"2020072712443348000_8.12.a029066.52","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.52.5.1072"},{"key":"2020072712443348000_8.12.a029066.53","doi-asserted-by":"publisher","DOI":"10.1016\/0092-8674(94)90337-9"},{"key":"2020072712443348000_8.12.a029066.54","doi-asserted-by":"publisher","DOI":"10.1111\/j.1527-3458.2007.00003.x"},{"key":"2020072712443348000_8.12.a029066.55","doi-asserted-by":"publisher","DOI":"10.1212\/01.wnl.0000327341.89587.76"},{"key":"2020072712443348000_8.12.a029066.56","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0b013e31822e55e7"},{"key":"2020072712443348000_8.12.a029066.57","doi-asserted-by":"publisher","DOI":"10.1177\/039463201402700201"},{"key":"2020072712443348000_8.12.a029066.58","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.53.3.466"},{"key":"2020072712443348000_8.12.a029066.59","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa051586"},{"key":"2020072712443348000_8.12.a029066.60","doi-asserted-by":"crossref","first-page":"1150","DOI":"10.1212\/01.wnl.0000265393.03231.e5","article-title":"Postwithdrawal rebound increase in T2 lesional activity in natalizumab-treated MS patients","volume":"70","year":"2008","journal-title":"Neurology"},{"key":"2020072712443348000_8.12.a029066.61","doi-asserted-by":"crossref","first-page":"5876","DOI":"10.4049\/jimmunol.154.11.5876","article-title":"T lymphocyte adhesion to human brain pericytes is mediated via very late antigen-4\/vascular cell adhesion molecule-1 interactions","volume":"154","year":"1995","journal-title":"J Immunol"},{"key":"2020072712443348000_8.12.a029066.62","doi-asserted-by":"publisher","DOI":"10.1191\/1352458504ms1084oa"},{"key":"2020072712443348000_8.12.a029066.63","doi-asserted-by":"publisher","DOI":"10.1002\/bdrb.20189"},{"key":"2020072712443348000_8.12.a029066.64","doi-asserted-by":"publisher","DOI":"10.1038\/356063a0"},{"key":"2020072712443348000_8.12.a029066.65","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2007-10-120329"}],"container-title":["Cold Spring Harbor Perspectives in Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1101\/cshperspect.a029066","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T18:37:26Z","timestamp":1719859046000},"score":1,"resource":{"primary":{"URL":"http:\/\/perspectivesinmedicine.cshlp.org\/lookup\/doi\/10.1101\/cshperspect.a029066"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,3,2]]},"references-count":65,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2018,12,3]]},"published-print":{"date-parts":[[2018,12]]}},"alternative-id":["10.1101\/cshperspect.a029066"],"URL":"https:\/\/doi.org\/10.1101\/cshperspect.a029066","relation":{},"ISSN":["2157-1422"],"issn-type":[{"value":"2157-1422","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,3,2]]}}}